Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 1
© 2008 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Oliver, R. T. Search for Related Content PubMed Articles by Oliver, R. T.

Abstract

Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214)

St. Bartholomew's Hospital, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom;

1

Background: At ASCO 2004 we reported a randomised trial (MRC TE19, EORTC 30982) comparing 1 course carboplatin (C) at AUCx7 with adjuvant radiotherapy (RT) for stage I seminoma. With median follow-up (FU) of 4 yrs, C was shown to be non-inferior for relapse free rate (1° outcome) and there was a reduction in contralateral testicular gem cell cancers (GCT). Because late relapses and 2^nd GCT can occur beyond 5 and 10 yrs we have continued FU of these patients (pts). We report the updated results, and further analysis of C dose and outcome in relation to method of assessing renal function. Methods: The 1° randomisation was RT versus one injection of C dosed at 7x (GFR+25) based on EDTA(n=357) and 90% of this dose if based on creatinine clearance(n=202). The trial was powered to exclude absolute differences in the 2 yr relapse-free rates (RFR) of > 3%. RFR were determined by the Kaplan-Meier method, and hazard ratios (HR) from the Cox regression model; HR>1 favors RT. Results: Between 1996–2001, 1447 pts were randomised in a 3:5 ratio (C=573, RT=904). Median FU is now 6.5 yrs with documented minimum 5 yr FU on 1148 pts. RFRs at 5 yrs are 95% (C) and 96% (RT) (HR 1.25, 90% CI 0.83, 1.89); an increase in 5yr RFR of >3.6% can be excluded with 95% confidence. Only one death from seminoma (RT) has been reported. There was a significant difference in the rate of new GCTs (2 on C vs 15 on RT), giving a HR of 0.22 (95% CI 0.05, 0.95 p=0.03). High levels of pre-treatment FSH (>12 iu/L) were associated with an increased risk of developing a 2nd GCT (HR: 8.57 (95% CI 1.82 –40.38)) Analysing the variation in dose received in the C group, showed that those who received at least 99% of the 7AUC dose (n=347) ignoring GFR method had 5 yr RFR of 96.1% (95% CI 93.4–97.7) compared with 92.6% (88.0–95.5) in those who received lower doses (n=212, HR: 0.51 (0.24 - 1.07) p=0.08)). Analysis of the available data on pathological risk factors demonstrated that larger tumours (>4cm) had poorer RFR (HR: 3.68 (1.49 - 9.13)). Conclusion: With prolonged FU this trial confirms the non-inferiority of single dose C (AUC7) vs RT in terms of RFR but with a reduced risk of 2^nd GCT in the C arm. The observation on the impact of C dosage, though not significant in its own right, reinforces the safety of adequately dosed C and may support studies of higher dose C.

Author Disclosure

Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Medical Research Council (non-commercial sponsor)

Abstract presentation from the 2008 ASCO Annual Meeting